Four new DRGs for surgical placement and removal of a heart rhythm monitor in the Dutch DRG package for 2022

20

May 2021

Heart surgeons and cardiologists sometimes implant or remove a heart rhythm monitor. There are specific procedure codes for this intervention: 039698 "Insertion of a subcutaneously placed heart rate monitor" and 039699 "Removal of a subcutaneously placed heart rate monitor". However, in the current version of the Dutch DRG package, these procedures cannot be reimbursed when performed by the specialist with the cardiopulmonary surgery profile.

On April 29, 2021, the Dutch Healthcare Authority (NZa) published the first release of the DRG package for the 2022 (RZ22a). Since 2022, a diagnosis of cardiac rhythm monitor implantation for medical specialty "Cardiopulmonary surgery" (0328_2290) will be implemented. In combination with procedure codes for insertion and removal of subcutaneously placed heart rate monitor, it will drive the allocation to four new DRGs under the DRG group 099899 "Cardiovascular system - Other heart diseases / acute rheumatism (including (sub) acute rheumatoid arthritis) / chronic rheumatic heart disease".

The following new DRGs will be implemented for adult patients:

  • 099899121 "Surgical placement of a heart rhythm monitor during hospital admission for (research into) a disease of the heart";
  • 099899122 "Surgical placement of a heart rate monitor at (research into) a disease of heart";
  • 099899123 "Removal of a heart rhythm monitor during hospital admission for (research into) a disease of the heart";
  • 099899124 "Removal of a heart rhythm monitor in case for (research into) a disease of the heart".

All DRGs have a tariff negotiated locally between providers and insurers. The effective date of the release is January 1, 2022.

The full details in Dutch can be found here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

24

Mar 2022

The HTA body of the Tuscany Regional Healthcare issues two types of documents: HTA forms and motivational forms. With a regional decree 2472 of February 10, 2022, Tuscany Regional Healthcare has published assessments of five medical devices of various therapeutic areas, such as cardiovascular and peripheral vascular areas.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more

18

Feb 2022

Dutch Organization for Health Research and Development, ZonMw awarded eight projects under the "Healthcare Evaluation and Appropriate Use" program, including two projects for geriatric care, two projects for cancer, per one project for cardiovascular, neurovascular, and dermatology care.

Read more

15

Feb 2022

In January 2022, the Basque Office for Health Technology Assessment (OSTEBA) released an HTA report aiming to assess and compare the efficacy, effectiveness, and safety of the mechanical circulatory support devices most used in the healthcare setting for the treatment and prevention of cardiogenic shock, including Impella® devices, intra-aortic balloon pumps, and extracorporeal membrane oxygenation.

Read more